Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NGI226 · 1 trial · 1 indication
AEs and SAEs including ECG parameters, Lab Chemistry and Hematology parameters, urinalysis, local tolerability
| Arm | Type | Description |
|---|---|---|
| NGI226 | EXPERIMENTAL | single peritendon injection |
| Placebo | PLACEBO_COMPARATOR | single peritendon injection |
| Name | Type | Description |
|---|---|---|
| NGI226 | DRUG | NGI226 MP |
| Placebo | DRUG | Placebo MP |
Inclusion Criteria: * Written informed consent must be obtained prior to all study specific screening procedures, as close to the start of the screening period as possible. * Presence of clinically (local Achilles tendon pain on tendon-loading activities, pain on palpation at the level 2-6 cm proxi...
NGI226 is an investigational small molecule being developed for Achilles tendinopathy, a musculoskeletal condition affecting the Achilles tendon. It is formulated as microparticles for local administration. The drug is currently in clinical development and has completed a Phase 2 trial, but it is not yet approved by regulatory authorities.
The specific molecular target of NGI226 has not been disclosed in available information. The drug is a small molecule formulated as microparticles, intended for the treatment of Achilles tendinopathy. Its mechanism of action is not publicly detailed, and no target class has been specified in the clinical trial data.
NGI226 is being developed by Novartis AG, a global pharmaceutical company listed on the New York Stock Exchange under the ticker NVS. Novartis is conducting clinical research on this investigational drug for Achilles tendinopathy, with a completed Phase 2 study evaluating its safety and preliminary efficacy.
NGI226 is in Phase 2 clinical development. A Phase 2 trial has been completed, but the drug remains investigational and has not received FDA approval. It is still in the clinical research stage, and further studies may be needed to establish its safety and efficacy before any regulatory submission.
NGI226 has one completed clinical trial, identified as NCT05592990, titled "A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy." This Phase 2, randomized, double-blind, placebo-controlled study enrolled 45 participants across the United States, France, and Germany.
No alternative names for NGI226 have been reported in the available clinical trial information. The drug is identified solely by its code name NGI226 in the context of its Phase 2 study for Achilles tendinopathy. No other designations or brand names are associated with this investigational agent.